Today, Wall Street Reports announced new research reports highlighting Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Forest Laboratories, Inc. (NYSE: FRX), Pharmacyclics (NASDAQ: PCYC), Cubist Pharmaceuticals, Inc.

Ranbaxy, Teva and other generic-drug makers are coming to grips with a drop in blockbuster brand-name medicines going off patent. One strategy: selling brand-name medicines.

By ATLnsider:Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.On May 8, 2013, Alexza Pharmaceuticals, Inc (ALXA) and Teva Pharmaceuticals USA, Inc (TEVA) announced that the two companies have ente

Score one for the branded drugs.

Teva and Sun Pharma to pay out to Pfizer and Takeda to settle long-running patent dispute in the US over stomach acid treatment

By Kapitall:Teva Pharmaceuticals (TEVA) is one step closer to selling its morning-after pill, Plan B One-Step, to women of all ages. The US government had previously opposed the sale of the drug without an age restriction, but yesterday filed a lette

Teva Pharmaceutical and Sun Pharmaceutical agreed Wednesday to pay $2.15 billion in patent-infringement damages to Pfizer and Takeda Pharmaceutical.

(Reuters) - Pfizer Inc said Teva Pharmaceuticals Industries Ltd and Sun Pharmaceutical Industries Ltd would pay $2.15 billion to settle a patent infringement lawsuit related to its acid-reflux drug Protonix.

* Teva to pay $1.8 bln, half this year and rest by Oct 2014

* Teva to pay $1.8 bln, half this year and rest by Oct 2014

Pfizer said it reached a $2.15 billion settlement with Teva Pharmaceuticals Industries and Sun Pharmaceutical Industries related to patent infringement on its acid-reflux drug Protonix.    

Pfizer has reached a $2.15 billion settlement with the two companies over patent infringement on its acid-reflux drug Protonix.

NEW YORK (MarketWatch) -- Pfizer Inc.said Wednesday that it reached a settlement with Teva Pharmaceuticals Industriesand Sun Pharmaceutical Industriesover patent infringement. The $2.15 billion deal ends a 10-year legal battle over a Pfizer-developed

June 12 (Reuters) - Pfizer Inc said it reached a $2.15 billion settlement with Teva Pharmaceuticals Industries Ltd and Sun Pharmaceutical Industries Ltd related to patent infringement on its acid-reflux drug Protonix.

June 12 (Reuters) - Pfizer Inc said it reached a $2.15 billion settlement with Teva Pharmaceuticals Industries Ltd and Sun Pharmaceutical Industries Ltd related to patent infringement on its acid-reflux drug Protonix.

2 examples of how past mistakes can be corrected, 1 hedge

The decision to allow adolescents to buy the pill without a prescription has done nothing to improve the stock value of Teva Pharmaceuticals, the company that makes Plan B One-Step.    

By Kevin Quon:Dr. Phillip Frost, CEO of Opko Health Inc (OPK), appears unwilling to see a falling share price in his latest project company. The well-renowned Chairman of the Board for the generic drug champion Teva Pharmaceutical Industries Ltd (TEV

In trading on Friday, shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) crossed above their 200 day moving average of $39.33, changing hands as high as $39.72 per share. Teva Pharmaceutical Industries Ltd shares are currently trading up about

JERUSALEM, June 3 (Reuters) - Israel's Teva Pharmaceutical Industries has moved closer to selling its Lonquex drug for the treatment of neutropenia, a complication of chemotherapy, after a panel recommended its sale in the European Union.

JERUSALEM, June 3 (Reuters) - Israel's Teva Pharmaceutical Industries has moved closer to selling its Lonquex drug for the treatment of neutropenia, a complication of chemotherapy, after a panel recommended its sale in the European Union.

JERUSALEM, June 3 (Reuters) - Israel's Teva PharmaceuticalIndustries has moved closer to selling its Lonquex drugfor the treatment of neutropenia, a complication ofchemotherapy, after a panel...

Teva Pharmaceutical Industries Ltd.

NEW YORK (TheStreet) - Watson Pharmaceuticals, founded by a Taiwanese immigrant in the early 1980s and now a rival to generic drug giants Teva Pharmaceuticalsand Novartis , is such an American success story the company has wound up in Ireland.On Mond

By StockRiters:Teva Pharmaceutical (TEVA) is a widely followed Israel-based global pharmaceutical company; however, besides its popular Copaxone drug, I did not find a lot of studies about the other drug candidates in its pipeline. The company is pri

ByBio Matt:Alexza Pharmaceuticals (ALXA) recently announced that it had struck a licensing deal with Teva Pharmaceuticals (TEVA) for commercialization of Adasuve in the U.S. The licensing and supply agreement for ADASUVE (loxapine) inhalation powder

ByAvi Greenberg:Shares of Alexza Pharmaceuticals (ALXA) soared to gains of more than 50% during premarket hours on Wednesday May 8 after announcing a licensing deal with Teva Pharmaceuticals (TEVA). The stock has since fallen lower by 20%, and is cur

ByEmerging Equities:A study released by the IMS Institute for Health Informatics finds that per capita spending on medicines declined by $33 in 2012. On one side, the report raises the question of whether this is good or bad. Is it due to better util

TEL AVIV, May 8 (Reuters) - Teva Pharmaceutical Industries and Alexza Pharmaceuticals reached an exclusive U.S. license and supply agreement for Adasuve inhalation powder for the treatment of agitation associated with schizophrenia or bipolar I disor

TEL AVIV, May 8 (Reuters) - Teva Pharmaceutical Industries and Alexza Pharmaceuticals reached an exclusive U.S. license and supply agreement for Adasuve inhalation powder for the treatment of agitation associated with schizophrenia or bipolar I disor

Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S.

By ChinaBio Today: Teva Pharmaceutical (NYSE: TEVA), the world's largest generic drug manufacturer and one of the world's fifteen largest pharmas, does not have a substantial presence in China. But the company's CEO, Jeremy Levin, believes China is

Just the facts, Fool.

Here's your Cheat Sheet to earnings...

Teva Pharmaceutical Industries Ltd (TEVA)Q12013 Earnings CallMay 02, 2013 8:00 am ETExecutivesKevin Mannix - Vice President, Head of Global Investor RelationsJeremy Levin - President, Chief Executive OfficerEyal Desheh - Chief Financial Officer, Grou

TEL AVIV, May 2 (Reuters) - Teva Pharmaceutical Industries is banking on approval in early 2014 for a new thrice-weekly version of its multiple sclerosis treatment Copaxone to bolster sales ahead of a likely onslaught from copies of its best-selling

JERUSALEM, May 2 (Reuters) - Teva Pharmaceutical Industries, the world's largest generic drugmaker, expects U.S.regulators to act on its more convenient three-times-a-weekdosing regimen of...

JERUSALEM, May 2 (Reuters) - Teva Pharmaceutical Industries , the world's largest generic drugmaker, expects U.S. regulators to act on its more convenient three-times-a-week dosing regimen of multiple sclerosis drug Copaxone in early 2014.

May 2 (Reuters) - Teva Pharmaceutical Industries Chief Financial Officer Eyal Desheh says:

TEL AVIV, May 2 (Reuters) - Teva Pharmaceutical Industries posted lower first-quarter profit as its revenue in the United States was hurt by a drop in sales of a key product due to generic competition.

TEL AVIV, May 2 (Reuters) - Teva Pharmaceutical Industries posted lower first-quarter profit as its revenue in the United States was hurt by a drop in sales of a key product due to generic competition.

May 1 (Reuters) - Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.

Wall Street is expecting lower profit for Teva Pharmaceutical Industries (TEVA) when the company reports its first quarter results on Thursday, May 2, 2013. Analysts are expecting earnings per share of $1.10 after the company booked a profit of $1.47